DarioHealth Corp.DRIO

DarioHealth Corp. (DRIO) reported a net loss of $8.2m for the quarter ending 31 March 2026, according to its most recent 10-Q filing, despite posting a headline diluted EPS of $1.25. Operating cash flow was a negative $6m, and the company’s cash and equivalents stood at $15m, while short-term investments added another $5m. The balance sheet shows $103.3m in total assets against $62.4m in stockholders’ equity, with inventory net of $4.2m and a modest $31k spent on property, plant, and equipment. Research and development expense clocked in at $2.4m, a figure that feels less like innovation funding and more like the cost of keeping the lights on.

DarioHealth’s product pages still trumpet a blood-pressure monitor that tracks results on your smartphone and glucose test strips that require no coding, but the company’s filings tell a different story. The 424B5 registration statement lists Twill, Inc. and DarioHealth Services Pvt. alongside Delaware-registered entities, while the product rail shows the same cuffs and strips it has been selling for years. The gap between the platform’s promise of ‘simple and accurate’ health monitoring and the filing’s cold numbers is now too wide to ignore. The company’s operating loss of $7.3m for the quarter underscores the tension between selling hardware and funding software, especially when the cash burn outpaces the revenue.

The company’s 10-Q for Q1 2026 provides the hard numbers: net loss attributable to parent of $8.2m, operating loss of $7.3m, and a $6m operating cash burn. Inventory fell by $144k, which could signal tighter operations or a clearance sale in progress. The company’s cash position of $15m and short-term investments of $5m give it a modest runway, but the $2.4m R&D line feels like a rounding error against the burn rate. The diluted weighted average shares outstanding of 6.6m and the $1.25 EPS figure are the kind of optics that make a loss look like a win, at least on paper.

DarioHealth’s registered trademarks span Delaware, India, Brazil, the EU, and WIPO, as detailed in its latest 424B5 filing. Yet the company’s product pages on MyDario still sell the same glucose strips and blood-pressure cuffs it has marketed for years, with no sign of a new blockbuster launch. The operating business is still selling hardware to consumers, while the filings suggest the bigger challenge is managing the cash burn and the inventory cycle. The product rail shows the Dario™ Blood Glucose Test Strips and the Automatic Blood Pressure Monitor as available for purchase, but the financial rail shows a company that’s still figuring out how to turn sales into sustainable margins.

The company’s latest 8-K from 22 July 2026 and its 10-Q from 13 May 2026 are the primary sources for the financial facts cited here. The product pages on MyDario provide the consumer-facing evidence of the company’s current offerings, while the 424B5 filing lists the corporate registrations and trademark scope. The operating reality-selling glucose strips and blood-pressure cuffs-is clear, but the path to profitability remains shrouded in the same opacity as the company’s R&D budget.